Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Chromosomal rearrangement-enhanced mRNA stability drives the carcinogenicity of oncofusion in pediatric leukemia

ABSTRACT: Acute lymphoblastic leukemia (ALL), the most common type of pediatric leukemia, is directly driven by chromosomal rearrangement-induced fusion genes. Compared to wild-type genes, various oncofusions exhibit heightened expression levels and continuous enhanced function to drive tumorigenesis. However, the underlying mechanism by which chromosomal rearrangements lead to functional enhancement remains largely elusive. Meanwhile, although large-scale sequencing has illuminated numerous fusion events, most of their functional implications is unknown. Here, we uncover for the first time that mRNA stability enhancement is a common and important tumorigenic mechanism for oncogenic fusions, such as classical PAX5 fusions. Based on this universal mechanism, we have identified a novel oncogenic fusion, STK38-PXT1, which exhibits upregulated STK38 mRNA levels and directly drives the development of ALL. Mechanically, the increased mRNA stability arises from enhanced m6A modification of oncofusions, which is primarily due to “gene truncation”, such as PAX5 fusion, and “partner collaboration”, such as STK38-PXT1. Furthermore, IGF2BP3, an m6A reader specifically up-regulated in these fusions-driven leukemia, is crucial for maintaining the high mRNA stability of oncofusions. We further propose venetoclax as an innovative and clinically available drug for ALL driven by these high-stability oncofusions. Our study not only sheds light on mRNA stabilization as a general mechanism for fusions to drive tumorigenesis, but also presents a promising therapeutic drug target and strategy for ALL patients.

ORGANISM(S): Mus musculus

PROVIDER: GSE275289 | GEO | 2026/01/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Large-scale discovery of chromatin dysregulation induced by oncofusions and other protein-coding variants

Project description:Although population-scale databases have expanded to millions of genetic variants, mechanistic insight into variant function has not kept pace. We present PROD-ATAC, a high-throughput method for discovering the effects of protein-coding variants on chromatin regulation. A pooled library of variants is expressed in a disease-agnostic biosensor cell line, and single-cell ATAC resolves each variant’s effect on chromatin. Using PROD-ATAC, we characterized the impacts of >100 oncogenic fusions and controls. We showed that pioneer activity is a common feature of fusions spanning an enormous range of frequencies. Further, fusion-induced dysregulation can be context-agnostic as observed mechanisms overlapped with cancer and cell-type specific prior knowledge. We also showed that gain-of-function pioneering is a common feature among oncofusions. This work provides a global view of fusion-induced chromatin disruption across many fusion frequencies and cancer types. Systematically dissecting this landscape revealed convergent mechanisms among seemingly disparate oncofusions and shared modes of chromatin dysregulation across different cancers.

2024-07-24 | GSE243553 | GEO

PAX5-KIDINS220 gene expression array in Ba/F3 cells

Project description:PAX5-KIDINS220 (PAX5-K220) is a novel chimeric fusion gene identified in a pediatric Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL) patient, but the function of the encoded fusion protein has not yet been analyzed.We successfully generated PAX5-K220 expressing cells and demonstrate that PAX5-K220 is a nuclear protein. In addition, PAX5-K220 activates JAK2-STAT5 pathway through the repression of Socs5, a known negative regulator of JAK-STAT pathway. However, although identified in Ph-like ALL, PAX5-K220 does not induce IL-3-independent proliferation when transduced in the IL-3-dependent Ba/F3 murine leukemia cells, but rather attenuates growth. Luciferase reporter assay reveals that PAX5-K220 inhibits wild type PAX5 transcriptional activity in a dominant-negative fashion like other PAX5-related fusion proteins, and may contribute to lymphocyte differentiation block. These results reveal that PAX5-K220 certainly shares the character with other PAX5-related fusion proteins rather than other fusion proteins with tyrosine kinase activity identified in Ph-like ALL, and did not contribute to proliferation activity.

2019-03-01 | GSE127485 | GEO

CPSF6-RARγ Interacts with HDAC3 to Promote Myeloid Transformation [CUT&Tag in CD34+ cells]

Project description:Acute myeloid leukemia (AML) with RARG fusions, which clinic features resemble acute promyelocytic leukemia (APL), have been identified as a new subtype with poor clinical outcomes. The underlying mechanism of RARG fusion is poorly understood, which needs to be explored urgently to develop effective therapeutic strategies. Using hematopoietic specific knock-in mouse model and xenograft mouse model transplanted with oncogene transduced human CD34+ cells, we revealed that CPSF6-RARG (CR) fusion, one of the most prevalent recurrent RARG translocations, enhances expansion of immature cells and impairs myeloid maturation, synergizing with RAS mutation to drive more aggressive myeloid malignancies. Mechanistically, CR recruits the histone deacetylase 3 (HDAC3) to suppress the transcription of PU.1, a key transcription factor for myeloid lineage specification. CR driven leukemia is more sensitive to HDAC inhibitors in vitro and in vivo. Hence, our data reveals the molecular bases of the oncogenic CR fusion and provides a potential targeted therapeutic approach against AML with CR fusions.

2024-10-24 | GSE245012 | GEO

CPSF6-RARγ Interacts with HDAC3 to Promote Myeloid Transformation [RNA-seq]

2024-10-24 | GSE243817 | GEO

CPSF6-RARγ Interacts with HDAC3 to Promote Myeloid Transformation [CR-N_mice_scRNA-seq]

2024-10-24 | GSE247606 | GEO

CPSF6-RARγ Interacts with HDAC3 to Promote Myeloid Transformation [human CD34+ cells_CUT-Tag seq_HDAC3]

2024-10-24 | GSE273551 | GEO

CPSF6-RARγ Interacts with HDAC3 to Promote Myeloid Transformation [human CD34+ cells_CUT-Tag seq_ H3K27me3]

2024-10-24 | GSE273550 | GEO

CPSF6-RARγ Interacts with HDAC3 to Promote Myeloid Transformation [BM Mac1+ and c-kit+ cells RNA-seq]

2024-10-24 | GSE245028 | GEO

Hoxblinc lncRNA reprograms CTCF-independent TADs to drive leukemic transcription and HSC dysregulation in NUP98 fusion transformed leukemia [RNA-Seq]

Project description:We found NUP98 fusions activate Hoxb-associated lncRNA, HoxBlinc that occupies and regulates homeotic/oncogenic topologically associated domain (TAD) in malignant hematopoiesis. Aberration of HoxBlinc led to recruitment of MLL1 complex , altered chromatin landscape (both H3K4me3 and chromatin accessibility), and HOX/homeotic gene activatiion in NUP98-PHF23 fusion driven leukemia and HoxBlinc -Tg models. Conversely, eliminated HoxBlinc in NUP98 fusion-driven leukemic cells resulted in loss of Hoxblinc binding, TAD integrity, recruitment of MLL complex, and MLL driven H3K4me3 and chromatin accessibility within the HoxBlinc defined domain in a CTCF independent manner, leading to inhibiting homeotic/leukemic oncogenes and mitigating NUP98 fusion-driven leukemia in xenografted mouse models. Thus, our studies revealed a CTCF independent role of HoxBlinc in leukemic TAD organization and oncogenic gene regulatory networks in NUP98-fusion related leukemia.

2025-01-31 | GSE269226 | GEO

A SIRT7-dependent acetylation switch regulates early B-cell differentiation and lineage commitment through PAX5

Project description:B lymphopoiesis is a key developmental event orchestrated by a complex combinatorial action of lineage-specific transcription factors. In early B cell progenitors, lineage commitment is directly mediated by the master regulator PAX5, whose deficiency is commonly associated with B cell Acute Lymphoblastic Leukemia (B-ALL). Despite its essential role in mammalian immunity, the regulatory mechanisms that control PAX5 function remain largely unknown. Here we show that NAD+-dependent enzyme SIRT7 coordinates B cell development progression through PAX5. We have identified a SIRT7-dependent regulatory switch based on dynamic deacetylation of a single PAX5 residue, which controls its activity and thereby B cell fate. While a PAX5K198 acetylated mimic is incapable of inducing both B cell development and identity due to reduced protein stability and impaired binding to chromatin, deacetylation of this residue boosts PAX5 activity, leading to massive gene repression and in vivo restoration of B cell commitment but not differentiation. These findings suggest an unexpected uncoupling of hematopoietic differentiation and lineage commitment. Further supporting the functional relevance of the SIRT7-PAX5 axis, the interplay between both factors is conserved in human B-ALL, where high SIRT7 expression is an independent good prognostic factor. Our findings unveil a crucial mechanism in the regulation of B cell production based on the control of PAX5 function and underscore the key role of Sirtuins in the regulation of the immune system.

2024-09-20 | PXD046457 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data